Pharmaceutical Executive podcast

Pharmaceutical Executive Daily: FDA Approves Pimjetmi

0:00
2:14
Recuar 15 segundos
Avançar 15 segundos
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

Mais episódios de "Pharmaceutical Executive"